Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How do you image when using DIBH with breast treatment?
Do you use portal or orthogonal imaging or both?
Answer from: Radiation Oncologist at Community Practice
For patients undergoing DIBH we use standard portal imaging only.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
VisionRT/OSMS daily with weekly standard ports
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
We use daily imaging of one tangential field . To minimize dose and exposure we only take one image of actual field and not double exposure with open field
Sign In
or
Register
to read more
5160
5179
5178
Related Questions
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
What are your top takeaways in Breast Cancer from ASCO 2025?
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
Do you boost a breast cavity for a high Ki-67 index in the absence of other risk factors?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
Would you consider APBI in a patient who meets all criteria but has high-risk genomic testing and is not receiving chemotherapy?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?